Biogen (BIIB) Income from Non-Controlling Interests (2009 - 2023)
Biogen (BIIB) recorded quarterly Income from Non-Controlling Interests of -$800000.0 in Q4 2023, down 300.0% quarter-over-quarter from -$200000.0 in Q3 2023, and up 11.11% on a YoY basis from -$720000.0 in Q4 2022.
Biogen (BIIB) Income from Non-Controlling Interests (2009 - 2023) Analysis & Trends
Biogen's Income from Non-Controlling Interests history runs 13 years deep, the most recent figure standing at -$800000.0 for Q4 2023.
- In Q4 2023, Income from Non-Controlling Interests rose 11.11% year-over-year to -$800000.0; the TTM figure through Sep 2024 stood at -$800000.0 (down 366.67% YoY), while the FY2023 annual figure was $400000.0, up 100.47% from the prior year.
- Income from Non-Controlling Interests was -$800000.0 for Q4 2023 at Biogen, down from -$200000.0 in the prior quarter.
- In the past five years, Income from Non-Controlling Interests ranged from a high of $577.0 million in Q2 2021 to a low of -$388.7 million in Q4 2021.
- Historically, Income from Non-Controlling Interests has averaged $9.2 million across 4 years, with a median of -$300000.0 in 2020.
- Biggest YoY gain for Income from Non-Controlling Interests was 795.96% in 2021; the steepest drop was 129466.67% in 2021.
- A 4-year view of Income from Non-Controlling Interests shows it stood at -$300000.0 in 2020, then slumped by 129466.67% to -$388.7 million in 2021, then surged by 99.77% to -$900000.0 in 2022, then gained by 11.11% to -$800000.0 in 2023.
- The last three Income from Non-Controlling Interests figures came in at -$800000.0 (Q4 2023), -$200000.0 (Q3 2023), and $1.7 million (Q2 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 2.48 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | - |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 2.00 Mn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | -3.00 Mn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | - |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 8.00 Mn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 1.00 Mn |
| 10 | Biogen | 28.75 Bn | 24.47 Bn | 1.82 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -800,000.00 |
| Sep 30, 2023 | -200,000.00 |
| Jun 30, 2023 | 1.70 Mn |
| Mar 31, 2023 | -300,000.00 |
| Dec 31, 2022 | -900,000.00 |
| Sep 30, 2022 | 200,000.00 |
| Jun 30, 2022 | 700,000.00 |
| Mar 31, 2022 | -85.30 Mn |
| Dec 31, 2021 | -388.70 Mn |
| Sep 30, 2021 | -11.10 Mn |
| Jun 30, 2021 | 577.00 Mn |
| Mar 31, 2021 | -5.60 Mn |
| Dec 31, 2020 | -300,000.00 |
| Sep 30, 2020 | 2.40 Mn |
| Jun 30, 2020 | 64.40 Mn |
| Mar 31, 2020 | -6.50 Mn |
| Dec 31, 2018 | -1.90 Mn |
| Sep 30, 2018 | -1.50 Mn |
| Jun 30, 2018 | 48.40 Mn |
| Mar 31, 2018 | -1.70 Mn |